Using Baricitinib to help cure HIV in veterans
Leveraging Jak 1/2 Inhibition with Baricitinib Towards HIV Cure in the Veteran Population
This study is looking at how a medication called Baricitinib might help veterans with HIV by targeting hidden infected cells and reducing inflammation, with the goal of improving their overall health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Decatur, UNITED STATES) |
| Project ID | NIH-11071952 on NIH RePORTER |
What this research studies
This research investigates the use of Baricitinib, a Jak 1/2 inhibitor, to target and potentially eradicate HIV in the veteran population. It focuses on addressing the persistent latently infected cells that contribute to ongoing HIV infection and related health issues. The study aims to reduce chronic inflammation and improve overall health outcomes for veterans living with HIV by examining the effects of Baricitinib on immune activation markers. Participants will be monitored for safety and efficacy as the research progresses.
Who could benefit from this research
Good fit: Ideal candidates for this research are veterans living with HIV who are experiencing chronic inflammation and related health complications.
Not a fit: Patients who are not veterans or those who do not have HIV may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that helps cure HIV and improves the health of veterans living with the virus.
How similar studies have performed: Previous studies using Jak 1/2 inhibitors have shown promise in reducing immune activation in HIV patients, suggesting potential for success in this approach.
Where this research is happening
Decatur, UNITED STATES
- Veterans Health Administration — Decatur, United States (Active)
Researchers
- Principal investigator: Gavegnano, Christina — Veterans Health Administration
- Study coordinator: Gavegnano, Christina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.